Showing results (291-300 of 755) with videos related to
Sort By:
Pageof 76
Medrxiv : the Preprint Server for Health Sciences|May 7, 2026
Evaluation of the genome-informed risk assessment (GIRA) approach from eMERGE in an independent health systemSandra Lapinska, Xinzhe Li, Ravi Mandla, et al.Nature Communications|March 22, 2021
Disrupting upstream translation in mRNAs is associated with human diseaseDavid S M Lee, Joseph Park, Andrew Kromer, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2010
Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in miceEric T Alexander, Charulatha Vedhachalam, Sandhya Sankaranarayanan, et al.Circulation. Cardiovascular Quality and Outcomes|July 24, 2019
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular OutcomesKelly D Myers, Niloofar Farboodi, Mkaya Mwamburi, et al.Journal of Lipid Research|May 10, 2006
Substrate specificity of lipoprotein lipase and endothelial lipase: studies of lid chimerasNathalie Griffon, Elaine C Budreck, Christopher J Long, et al.Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|July 20, 2021
A Genome-First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult PopulationShadi Ahmadmehrabi, Binglan Li, Daniel Hui, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|July 7, 2007
Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and effluxGinny L Weibel, Eric T Alexander, Michelle R Joshi, et al.Circulation. Genomic and Precision Medicine|July 11, 2018
Multiplexed Targeted Resequencing Identifies Coding and Regulatory Variation Underlying Phenotypic Extremes of High-Density Lipoprotein Cholesterol in HumansSumeet A Khetarpal, Paul L Babb, Wei Zhao, et al.Journal of Lipid Research|August 5, 2018
Directional ABCA1-mediated cholesterol efflux and apoB-lipoprotein secretion in the retinal pigment epitheliumNicholas N Lyssenko, Naqi Haider, Antonino Picataggi, et al.Atherosclerosis|September 19, 2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE IEli M Roth, Patrick M Moriarty, Jean Bergeron, et al.Pageof 76